Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 21 patients with essential hypertension, all of whom completed the study, marked reductions in systolic and diastolic blood pressure were achieved under therapy withN-amidino-2-(2,6-dichlorophenyl)-acetamide hydrochloride (guanfacine, BS 100-141) administered 3 times daily in small to medium, gradually increasing doses. The lowest daily dose was 1 mg, the highest 10 mg, the average being 4 mg. Despite the low initial dosage and subsequent slow progression--designed to keep side effects within limits--BS 100-141 had a rapid and significant antihypertensive effect on both systolic and diastolic blood pressure. Habituation, with consequent loss of effect, was not observed. Laboratory parameters did not change, although blood sugar was reported to have shown a general tendency to rise in the study. Renal function and electrolytes remained normal. This new anithypertensive should probably be classified, as regards efficacy, alongside clonidine and methyldopa; it would also seem to be about as well tolerated as these two compounds. In order to prevent side effects, a gradually increasing low-dose regimen is recommended.
 ...
PMID:A new centrally action antihypertensive agent guanfacine (BS 100-141). 32 62

Sixteen patients with essential hypertension were treated with N-Amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride (BS 100--141) and clonidine for five weeks each in a double-blind cross-over trial. Dosage ranged from 2 to 6 mg BS 100--141 and from 0.3 to 0.9 mg clonidine daily in two or three divided doses. Both compounds caused a significant and comparable fall in blood pressure. Patients whose blood pressure was not reduced to normal levels by 2 to 3 mg BS 100--141 daily did not respond better to an increase in the dose. Dry mouth and constipation occurred about equally frequently with both agents, but sedation and orthostatic circulatory effects were considerably more frequent with clonidine. Rebound hypertension likewise occurred in five patients following clonidine withdrawal as opposed to no patient after BS 100-141.
 ...
PMID:Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. 34 14

Guanfacine (BS 100-141) (N-amidino-2-(2,6-dichlorophenyl)-acetamide hydrochloride) is a centrally acting alpha-adrenergic receptor agonist. A comparison of its anti-hypertensive effect with that of methyldopa was made in patients with essential hypertension. After a wash-out period of 8-10 days, 33 patients with hypertension of different degrees of severity were treated with guanfacine or methyldopa, both combined with clorexolone, in a randomized double-blind study extending over 8 weeks. Blood pressure was reduced significantly by both drug treatments, compared with the placebo. The incidence of side-effects with both drugs was low. Those that did occur decreased after adjustment of dosage. Guanfacine was clinically effective in all patients with various degrees of hypertension, but treatment with methyldopa was inadequate in 30% of patients even at maximum dosage. Up to 40 hours after abrupt drug withdrawal, no rebound hypertension was noted in the guanfacine group.
 ...
PMID:The antihypertensive effect of guanfacine compared with methyldopa. 610 13